Journal of Antimicrobial Chemotherapy (1999) 44, 11-15
© 1999 The British Society for Antimicrobial Chemotherapy
The socio-economic burden of influenza
Department of Medical Economics, University Hospital, Rämistrasse 100, CH-8091 Zürich, Switzerland
Influenza epidemics and pandemics have a huge impact on society and individuals. The weight and scope of the burden of influenza varies with the age and underlying health of the patient. The disease imposes a significant burden on all individuals, but hospitalization and treatment occur more frequently in high-risk patients (the elderly and those with certain underlying medical conditions); patient populations that are increasing in size. Escalating medical costs have increased the need to quantify the burden of influenza. The first step in any such analysis is to determine the incidence of the disease; with influenza, this is often under-reported, since the illness may be confused with other viral illnesses. In addition to the direct costs of medical care, the indirect costs of influenza are substantial and stem largely from absenteeism and loss of work productivity. Estimates of the cost of influenza in the USA, France and Germany have shown that indirect costs can be five– to 10–fold higher than direct costs. Other intangible costs associated with influenza include impaired performance, which can reduce reaction times, and adverse effects on the quality of life of patients and their families. The costs of interventions should, therefore, be considered in this context. The main approach to the control of influenza and its associated costs is the administration of vaccines. Although vaccines are widely effective, the greatest potential benefits are observed within high-risk groups; vaccination is therefore recommended in many countries for high-risk patients, their carers and healthcare workers. However, the shortcomings of present vaccines, which include manufacturing limitations that prevent guaranteed adequate supply of vaccine, the difficulty in matching vaccines to circulating strains and the need for administration by injection, highlight the need for complementary treatment.
Tel: +41-1-255-8591; Fax: +41-1-255-8592; E-mail: thomas.szucs{at}vdi.usz.ch
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Machado, J. Ferreira, A. Novais, L. Peixe, R. Canton, F. Baquero, and T. M. Coque Preservation of Integron Types among Enterobacteriaceae Producing Extended-Spectrum {beta}-Lactamases in a Spanish Hospital over a 15-Year Period (1988 to 2003) Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2201 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kramer, C. Durham, T. Schroeder, and J. C. Garrelts Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2111 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Kaczmarek, F. Dib-Hajj, W. Shang, and T. D. Gootz High-Level Carbapenem Resistance in a Klebsiella pneumoniae Clinical Isolate Is Due to the Combination of blaACT-1 {beta}-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-Regulation of the Phosphate Transport Porin PhoE. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3396 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Pan, R. Ye, D.-M. Meng, W. Zhang, H.-Q. Wang, and K.-Z. Liu Molecular characteristics of class 1 and class 2 integrons and their relationships to antibiotic resistance in clinical isolates of Shigella sonnei and Shigella flexneri J. Antimicrob. Chemother., August 1, 2006; 58(2): 288 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Skurnik, R. Ruimy, A. Andremont, C. Amorin, P. Rouquet, B. Picard, and E. Denamur Effect of human vicinity on antimicrobial resistance and integrons in animal faecal Escherichia coli J. Antimicrob. Chemother., June 1, 2006; 57(6): 1215 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Poole, T. R. Callaway, K. M. Bischoff, C. E. Warnes, and D. J. Nisbet Macrolide inactivation gene cluster mphA-mrx-mphR adjacent to a class 1 integron in Aeromonas hydrophila isolated from a diarrhoeic pig in Oklahoma J. Antimicrob. Chemother., January 1, 2006; 57(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rothberg, D. Fisher, B. Kelly, and D. N. Rose Management of Influenza Symptoms in Healthy Children: Cost-effectiveness of Rapid Testing and Antiviral Therapy Arch Pediatr Adolesc Med, November 1, 2005; 159(11): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ebner, K. Garner, and A. Mathew Class 1 integrons in various Salmonella enterica serovars isolated from animals and identification of genomic island SGI1 in Salmonella enterica var. Meleagridis J. Antimicrob. Chemother., June 1, 2004; 53(6): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Butaye, L. A. Devriese, and F. Haesebrouck Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria Clin. Microbiol. Rev., April 1, 2003; 16(2): 175 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Hartman, I. I. Essiet, D. W. Isenbarger, and L. E. Lindler Epidemiology of Tetracycline Resistance Determinants in Shigella spp. and Enteroinvasive Escherichia coli: Characterization and Dissemination of tet(A)-1 J. Clin. Microbiol., March 1, 2003; 41(3): 1023 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Reyes, H. Bello, M. Dominguez, S. Mella, R. Zemelman, and G. Gonzalez Prevalence and types of class 1 integrons in aminoglycoside-resistant Enterobacteriaceae from several Chilean hospitals J. Antimicrob. Chemother., February 1, 2003; 51(2): 317 - 321. [Abstract] [Full Text] [PDF]
|
|